TEXAS RETINA ASSOCIATES
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1966-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://www.texasretina.com
Clinical Trials
5
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
- Conditions
- UveitisUveitis, PosteriorUveitis, AnteriorUveitis, Intermediate
- Interventions
- Other: Sham Injection
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Texas Retina Associates
- Target Recruit Count
- 30
- Registration Number
- NCT05486468
- Locations
- 🇺🇸
Texas Retina Associates, Plano, Texas, United States
One Year Trial Evaluating Safety of Ozurdex With Eylea
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Texas Retina Associates
- Target Recruit Count
- 50
- Registration Number
- NCT03984110
- Locations
- 🇺🇸
Texas Retina Associates, Dallas, Texas, United States
Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
- Conditions
- Non-Ischemic Central Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Texas Retina Associates
- Target Recruit Count
- 68
- Registration Number
- NCT01295112
- Locations
- 🇺🇸
Texas Retina Associates, Dallas, Texas, United States
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Texas Retina Associates
- Target Recruit Count
- 12
- Registration Number
- NCT00570479
- Locations
- 🇺🇸
Texas Retina Associates, Arlington, Texas, United States
Ranibizumab and Reduced Fluence PDT for AMD
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Texas Retina Associates
- Target Recruit Count
- 60
- Registration Number
- NCT00527475
- Locations
- 🇺🇸
California Retina Consultants & Research Foundation, Santa Barbara, California, United States
🇺🇸Associated Retinal Consultants, Ann Arbor, Michigan, United States
🇺🇸Texas Retina Associates, Arlington, Texas, United States
News
EYP-1901 Shows Promise in Reducing Treatment Burden for Wet AMD Patients in Phase 2 DAVIO-2 Trial
EYP-1901, a pan-VEGF receptor inhibitor delivered via bioerodible implant technology, demonstrated non-inferiority to aflibercept in maintaining visual acuity in previously treated wet AMD patients over 32 weeks.